Pulmonary Disorders II
Cystic Fibrosis
Akkerman-Nijland AM, Akkerman OW, Grasmeijer F,
et al. The pharmacokinetics of antibiotics in cystic fibro-
sis. Expert Opin Drug Metab Toxicol. 2021;17:53-68.
https://doi.org/10.1080/17425255.2021.1836157
Dentice RL, Elkins MR, Middleton PG, et al. A ran-
domised trial of hypertonic saline during hospitalisation
for exacerbation of cystic fibrosis. Thorax. 2016;71(2):141-
147. https://doi.org/10.1136/thoraxjnl-2014-206716
Fajac I, Burgel PR, Martin C. New drugs, new challenges in
cystic fibrosis care. Eur Respir Rev. 2024;33(173):240045.
https://doi.org/10.1183/16000617.0045-2024
Flume PA, Amelina E, Daines CL, et al. Efficacy and
safety of inhaled dry-powder mannitol in adults with
cystic fibrosis: an international, randomized controlled
study. J Cyst Fibros. 2021;20(6):1003-1009. https://doi.
org/10.1016/j.jcf.2021.02.011
Flume PA, Mogayzel PJ Jr, Robinson KA, et al.
Cystic fibrosis pulmonary guidelines: treatment of
Med.
2009;180(9):802-808.
https://doi.org/10.1164/
rccm.200812-1845pp
Flume PA, Robinson KA, OβSullivan BP, et al. Cystic
fibrosis pulmonary guidelines: airway clearance thera-
pies. Respir Care. 2009;54(4):522-537. https://pubmed.
ncbi.nlm.nih.gov/19327189/
Gentzsch M, Mall MA. Ion channel modulators in
cystic fibrosis. Chest. 2018;154(2):383-393. https://doi.
org/10.1016/j.chest.2018.04.036
Goss CH, Heltshe SL, West NE, et al. A randomized
clinical trial of antimicrobial duration for cystic fibro-
org/10.1164/rccm.202102-0461oc
Grasemann H, Ratjen F. Cystic fibrosis. N Engl J
Med. 2023;389(18):1693-1707. https://doi.org/10.1056/
nejmra2216474
Harvey C, Weldon S, Elborn S, Downey DG, Taggart C.
The effect of CFTR modulators on airway infection in
cystic fibrosis. Int J Mol Sci. 2022;23(7):3513. https://doi.
org/10.3390/ijms23073513
Heinz KD, Walsh A, Southern KW, Johnstone Z, Regan
KH. Exercise versus airway clearance techniques for
people with cystic fibrosis. Cochrane Database Syst Rev.
2022;6(6):CD013285. https://doi.org/10.1002/14651858.
cd013285.pub2
Heltshe SL, West NE, VanDevanter DR, et al. Study
design considerations for the Standardized Treatment
of Pulmonary Exacerbations 2 (STOP2): a trial to
compare intravenous antibiotic treatment durations in
CF. Contemp Clin Trials. 2018;64:35-40. https://doi.
org/10.1016/j.cct.2017.11.012
Hong LT, Downes KJ, FakhriRavari A, et al.
International consensus recommendations for the use
of prolonged-infusion beta-lactam antibiotics: Endorsed
by the American College of Clinical Pharmacy, British
Society for Antimicrobial Chemotherapy, Cystic Fibrosis
Foundation, European Society of Clinical Microbiology
and Infectious Diseases, Infectious Diseases Society of
2023;43(8):740-777. https://doi.org/10.1002/phar.2842
Kapnadak SG, Dimango E, Hadjiliadis D, et al. Cystic
Fibrosis Foundation consensus guidelines for the care
of individuals with advanced cystic fibrosis lung dis-
ease. J Cyst Fibros. 2020;19(3):344-354. https://doi.
org/10.1016/j.jcf.2020.02.015
King CS, Brown AW, Aryal S, Ahmad K, Donaldson
S. Critical care of the adult patient with cystic fibrosis.
Chest.
2019;155(1):202-214.
https://doi.org/10.1016/j.
chest.2018.07.025
Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al.
Cystic fibrosis pulmonary guidelines. Chronic medica-
rccm.201207-1160oe
Sanders DB, Bittner RC, Rosenfeld M, Hoffman
LR, Redding GJ, Goss CH. Failure to recover to
baseline pulmonary function after cystic fibro-
Med.
2010;182(5):627-632.
https://doi.org/10.1164/
rccm.200909-1421oc
Smith S, Rowbotham NJ, Charbek E. Inhaled antibiotics
for pulmonary exacerbations in cystic fibrosis. Cochrane
Database Syst Rev. 2022;8(8):CD008319. https://doi.
org/10.1002/14651858.cd008319.pub4